Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  FUJIFILM Holdings Corporation    4901   JP3814000000

FUJIFILM HOLDINGS CORPORATION

(4901)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

REFILE-UPDATE 3-Fujifilm seeks approval for Avigan as COVID-19 treatment in Japan

10/15/2020 | 10:43pm EST

TOKYO, Oct 16 (Reuters) - Fujifilm Holdings Corp said on Friday it was seeking approval for its flu drug Avigan as a treatment for COVID-19 in Japan, a move that comes after a late-stage study showed reduced recovery time for patients with non-severe symptoms.

Shares of the company closed roughly 3% higher on the news.

The Nikkei newspaper last month cited https://asia.nikkei.com/Spotlight/Coronavirus/Japanese-approval-sought-for-Avigan-to-treat-COVID-19 ministry sources saying approval could be granted to the drug within a month of its application.

Japan has already approved Avigan, known generically as favipiravir, as an emergency flu medicine, which is the subject of at least 16 clinical trials around the world. But concerns remain, as the drug has been shown to cause birth defects in animal studies.

Japan's government has called on Fujifilm to triple national stockpiles of the drug. The company said in a statement it has been working with strategic partners to meet that goal and requests by other countries to supply the drug.

Fujifilm in July signed a deal with India's Dr Reddy's Laboratories and Dubai-based Global Response Aid to sell Avigan for COVID-19 globally, excluding in China, Japan and Russia.

The drug, known generically worldwide as favipiravir, has been approved in India and Russia to treat COVID-19.

Last month, Fujifilm said the late-stage study of 156 COVID-19 patients in Japan showed that symptoms of those treated with Avigan improved after 11.9 days, versus 14.7 days for a placebo group.

Results of the study, conducted by subsidiary Fujifilm Toyama Chemical, were found to be statistically significant. (Reporting by Chris Gallagher and Sayantani Ghosh; Editing by Stephen Coates, Edwina Gibbs and Shinjini Ganguli)


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
DR. REDDY'S LABORATORIES LIMITED -1.41% 4829.6 End-of-day quote.67.86%
FUJIFILM HOLDINGS CORPORATION -1.83% 5625 End-of-day quote.7.55%
NIKKEI 225 1.34% 26787.54 Real-time Quote.11.74%
US DOLLAR / RUSSIAN ROUBLE (USD/RUB) -0.04% 75.72 Delayed Quote.23.37%
All news about FUJIFILM HOLDINGS CORPORATION
11/13FUJIFILM : Cellular Dynamics and Lonza Agree to Expand the Availability and Use ..
AQ
11/05WHO-led COVID drug scheme doubles down on antibodies, steroids and shuns remd..
RE
11/05FUJIFILM HOLDINGS CORPORATION : half-yearly earnings release
10/30In Japan's Nagasaki, some glimmers of economic revival
RE
10/22FUJIFILM : Fuji Xerox in court over alleged unfair contract terms
AQ
10/22Dr Reddy's isolates data center services after cyberattack
RE
10/22Fujifilm partners Shanghai firm to seek China COVID-19 approval for Avigan
RE
10/21Fujifilm partners Shanghai firm to seek China COVID-19 approval for Avigan
RE
10/19Fujifilm seeks approval for Avigan as COVID-19 treatment in Japan
RE
10/16Fujifilm seeks approval for Avigan as COVID-19 treatment in Japan
RE
More news
Financials
Sales 2021 2 200 B 21 092 M 21 092 M
Net income 2021 127 B 1 218 M 1 218 M
Net Debt 2021 170 B 1 626 M 1 626 M
P/E ratio 2021 17,7x
Yield 2021 1,70%
Capitalization 2 266 B 21 715 M 21 731 M
EV / Sales 2021 1,11x
EV / Sales 2022 1,04x
Nbr of Employees 73 906
Free-Float 73,8%
Chart FUJIFILM HOLDINGS CORPORATION
Duration : Period :
FUJIFILM Holdings Corporation Technical Analysis Chart | 4901 | JP3814000000 | MarketScreener
Technical analysis trends FUJIFILM HOLDINGS CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 6 164,67 JPY
Last Close Price 5 669,00 JPY
Spread / Highest target 21,7%
Spread / Average Target 8,74%
Spread / Lowest Target -11,4%
EPS Revisions
Managers
NameTitle
Shigetaka Komori Chairman & Group Chief Executive Officer
Kenji Sukeno President, Group COO & Representative Director
Takashi Iwasaki Director & Chief Technology Officer
Kouichi Tamai Director & Vice President
Takatoshi Ishikawa Director
Sector and Competitors
1st jan.Capitalization (M$)
FUJIFILM HOLDINGS CORPORATION7.55%21 550
CANON INC.-37.94%18 576
BROTHER INDUSTRIES, LTD.-11.93%4 980
RICOH COMPANY, LTD.-41.53%4 839
TOSHIBA TEC CORPORATION-17.04%1 977
KONICA MINOLTA, INC.-53.16%1 586